InvestorsHub Logo
Followers 578
Posts 27173
Boards Moderated 1
Alias Born 03/18/2015

Re: aheadofthecurve post# 70050

Wednesday, 06/30/2021 8:37:51 AM

Wednesday, June 30, 2021 8:37:51 AM

Post# of 118425
Wow! Great News Out! IP advancing baby! NR2F6!

SAN FRANCISCO, CA / ACCESSWIRE / June 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. (the "Company") is developing a program to establish the use of its license utilizing NR2F6 agonists and antagonists coupled with the proprietary drug delivery systems in the treatment of various disorders including human pancreatic cancer and colon cancer. The work the Company is contracting to conduct is intended to do pre-clinical trials leading into seeking FDA approval for the combined efforts. Our team of industry experts and advisors have the expertise to lead the Company to efficiently conduct this next phase of development.
The developing program will allow Oncology Pharma to begin its own path towards producing proprietary intellectual property, for the pursuit and development of new therapies. The Company's established portfolio of licensing agreements is expected to allow the company the ability to develop its own innovations to stand out amongst its peers.


Sometimes its Skil, Sometimes its Luc.

I Appreciate All Member Follows!

Desperate Sellers Become Desperate Buyers. Vice Versa

ALL IMHO.